貝卡普勒明
| A+醫學百科 >> 藥品百科 >> 貝卡普勒明 |
貝卡普勒明（Becaplermin），As adjunct to good ulcer care practices to treat lower extremity diabetic neuropathic ulcers that extend into SC tissue or beyond and have adequate blood supply. Use for diabetic neuropathic ulcers that do not extend through dermis into SC tissue or ischemic ulcers has not been studied.
本藥品被歸類到激素藥物等藥品分類。
目錄 |
貝卡普勒明的副作用（不良反應）
General: Infection, cellulitis, osteomyelitis, erythematous rashes.
服用貝卡普勒明須注意的事項
Pregnancy Category: C
Contraindications: Known neoplasms at application site. Use in wounds that close by primary intention.
Special Concerns: Effect on exposed joints, tendons, ligaments, and bone has not been established. Use with other topical drugs has not been studied. Use with caution during lactation. Safety and efficacy have not been determined in children less than 16 years of age.
貝卡普勒明的用法用量
注意：同種藥品可由于不同的包裝規格有不同的用法或用量。本文只供參考。如果不確定，請參看藥品隨帶的說明書或向醫生詢問。
Gel, 0.01% Lower extremity diabetic neuropathic ulcers. Dose depends on size of ulcer area. To determine length of gel to be applied, measure greatest length of ulcer by greatest width of ulcer in either inches or centimeters. To calculate length of gel in inches:7.5 g or 15 g tube: length x width x 0.62 g tube: length x width x 1.3Generally, each square inch of ulcer surface will require about 2/3 inch from 7.5 g or 15 g tube and about 11/4 inches from 2 g tube.To calculate length of gel in centimeters:7.5 g or 15 g tube: length x width divided by 42 g tube: length x width divided by 2Generally, each square centimeter of ulcer surface will require about 0.25 cm of gel from 7.5 or 15 g tube or about 0.5 cm of gel from 2 g tube. Calculate
貝卡普勒明藥理作用
Classification: Topical wound healing drug Action/Kinetics: Topical recombinant human platelet-derived growth factor. Promotes chemotactic recruitment and proliferation of cells involved in wound repair and enhances formation of granulation tissue.
市場上的貝卡普勒明
- 貝卡普勒明
參看
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 關于“貝卡普勒明”的留言： |  訂閱討論RSS
|
|
目前暫無留言 | |
| 添加留言 | |